Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
26 févr. 2020 08h01 HE | Seelos Therapeutics, Inc.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Amendment of SLS-002 Agreement
21 oct. 2019 09h00 HE | Seelos Therapeutics, Inc.
Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Reports Q2 2019 Pipeline Update
01 août 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
Momentum for MEDICAL WORLD AMERICAS continues to grow
09 oct. 2013 15h02 HE | Medical World Americas
HOUSTON, TEXAS, Oct. 9, 2013 (GLOBE NEWSWIRE) -- MEDICAL WORLD AMERICAS has begun to reveal its extensive list of distinguished speakers for its 2014 conference, while also boasting rapid sales for...